Zoledronic acid for relapsed Langerhans cell histiocytosis with isolated skull bone lesion

Pediatr Int. 2019 Mar;61(3):315-317. doi: 10.1111/ped.13774. Epub 2019 Feb 21.

Authors

Ko Kudo¹, Tatsuhiko Tanaka², Akie Kobayashi¹, Kiminori Terui¹, Etsuro Ito¹

Affiliations

¹ Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan.
² Department of Pediatrics, Aomori Prefecture Hospital, Aomori, Japan.

PMID: 30793439
DOI: 10.1111/ped.13774

No abstract available

Keywords: Langerhans cell histiocytosis; childhood; zoledronic acid.

Publication types

Case Reports

MeSH terms

Biomarkers
Bone Density Conservation Agents / adverse effects
Bone Density Conservation Agents / therapeutic use*
Bone Diseases / drug therapy
Bone Diseases / etiology*
Child
Female
Histiocytosis, Langerhans-Cell / complications
Histiocytosis, Langerhans-Cell / drug therapy*
Humans
Magnetic Resonance Imaging
Recurrence
Skull / pathology*
Zoledronic Acid / adverse effects
Zoledronic Acid / therapeutic use*

Substances

Biomarkers
Bone Density Conservation Agents
Zoledronic Acid